Hair Study

RCH-01: Androgenetic Alopecia

In 2017, RepliCel completed a phase 1 human clinical trial of RCH-01 in patients with androgenetic alopecia. The study proved the product’s safety and provided very promising indications of the product’s efficacy in terms of minimizing hair loss and increasing hair density in a subset of patients. We are very excited about this product’s potential but have several steps to go yet before we can bring it to the market.

RCH-01 for Pattern Baldness

Cell Movement in the Hair Follicle Dermis More Than a Two-Way Street? Cell Movement in the Hair Follicle Dermis More Than a Two-Way Street?

Cultured Peribulbar Dermal Sheath Cells Can Induce Hair Follicle Development and Contribute to the D Cultured Peribulbar Dermal Sheath Cells Can Induce Hair Follicle Development and Contribute to the D

De Novo Production of Dermal Papilla Cells during the Anagen Phase of the Hair Cycle De Novo Production of Dermal Papilla Cells during the Anagen Phase of the Hair Cycle

Hair Follicle Dermal Stem Cells Regenerate the Dermal Sheath, Repopulate the Dermal Papilla, and Mod Hair Follicle Dermal Stem Cells Regenerate the Dermal Sheath, Repopulate the Dermal Papilla, and Mod

Phase I/IIa clinical trial for the treatment of androgenetic alopecia using intradermal injections of cultured autologous dermal sheath cup cells Phase I/IIa clinical trial for the treatment of androgenetic alopecia using intradermal injections of cultured autologous dermal sheath cup cells

Phase I/IIa Interim Results Phase I/IIa Interim Results

Plasticity and Cytokinetic Dynamics of the Hair Follicle Mesenchyme: Implications for Hair Growth Co Plasticity and Cytokinetic Dynamics of the Hair Follicle Mesenchyme: Implications for Hair Growth Co